Mersana Therapeutics, Inc. Common Stock (MRSN)
Mersana Therapeutics, Inc. is a biotechnology company focused on developing innovative antibody drug conjugates (ADCs) for the treatment of cancer. Founded in 2014, the company leverages its proprietary platform to design and develop highly targeted therapies aimed at difficult-to-treat tumors, with an emphasis on delivering potent medicines directly to cancer cells while minimizing damage to healthy tissue.
Company News
Mersana Therapeutics will report Q2 2025 financial results on August 13, 2025, and host a conference call. The company is developing antibody-drug conjugates (ADCs) for cancer treatment, with promising interim Phase 1 clinical data for their Emi-Le drug candidate.
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish So...
Mersana Therapeutics suffered a major trial failure for its lead candidate in July, causing a significant drop in stock value. Read more on MRSN stock here.
Mersana's stock tumbles 58% to mark its biggest-ever one-day percentage decline since going public in 2018.